Last Updated: July 11, 2026

Suppliers and packagers for plenvu


✉ Email this page to a colleague

« Back to Dashboard


plenvu

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Salix PLENVU ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 209381 NDA Salix Pharmaceuticals, Inc 65649-400-01 1 KIT in 1 CARTON (65649-400-01) * 46.26 POWDER, FOR SOLUTION in 1 POUCH * 55.65 POWDER, FOR SOLUTION in 1 POUCH * 115.96 POWDER, FOR SOLUTION in 1 POUCH 2018-05-04
Salix PLENVU ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 209381 NDA Salix Pharmaceuticals, Inc 65649-400-02 1 KIT in 1 CARTON (65649-400-02) * 46.26 POWDER, FOR SOLUTION in 1 POUCH * 55.65 POWDER, FOR SOLUTION in 1 POUCH * 115.96 POWDER, FOR SOLUTION in 1 POUCH 2018-05-04
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for plenvu

Last updated: June 2, 2026

PLENVU suppliers: Who manufactures, packages, and supplies Plenvu (macrogol 3350, sodium chloride, sodium bicarbonate, potassium chloride) for pharmacies and wholesalers?

PLENVU’s commercial supply chain is dominated by the MAH (marketing-authorisation holder) and packer-distributors that hold the EU/UK authorization and release products for the commercial market, plus upstream manufacturers that make bulk macrogol-based regimens and the finished, unit-dose components (sachets/solution). Public, consistently citable supplier detail is not available in the prompt, so a complete supplier map (by site, entity, and drug substance/finished-dose split) cannot be produced.

Who is the marketing-authorisation holder (MAH) and supply distributor for PLENVU?

Answer: Not provided in the input.

What to expect in PLENVU supply documentation

  • EU/UK authorization lists an MAH and manufacturing sites (bulk and finished dosage).
  • Wholesaler supply and pharmacy procurement typically route through the MAH’s local affiliate or contracted packer/releaser.

Which companies manufacture the bulk macrogol electrolyte regimen for PLENVU?

Answer: Not provided in the input.

Common PLENVU manufacturing categories

  • Bulk manufacture of macrogol 3350 blend and electrolyte components
  • Filling and sachet packaging (unit regimen components)
  • Finished product assembly and secondary packaging
  • Batch release by the authorized manufacturing site for each market

What suppliers provide PLENVU sachet packaging and unit-dose components?

Answer: Not provided in the input.

Packaging supply points typically listed for regimen products

  • Sachet-making and sealing
  • Printed-codified secondary packaging
  • Cold-chain is typically not required for macrogol-electrolyte products, but humidity control and desiccation steps may be included in facility controls.

Who supplies PLENVU to US distribution channels, and is it the same as EU/UK?

Answer: Not provided in the input.

US considerations for regimen products

  • US supply is usually driven by the NDA/ANDA label holder and contract manufacturing partners for finished dosage and packaging.
  • Cross-region sourcing can occur for bulk but US release often requires local/contract batch release arrangements.

What is PLENVU’s FDA status and how does that affect supplier mapping?

Answer: Not provided in the input.

Orange Book and listing implications

  • If there is no FDA approval record or if PLENVU is not marketed in the US, supplier mapping must be treated as EU/UK-centric.

Which upstream raw-material suppliers feed the PLENVU ingredient stack (macrogol 3350, electrolytes)?

Answer: Not provided in the input.

Raw ingredient categories

  • Macrogol 3350 (polyethylene glycol) polymer grade supply
  • Sodium chloride, potassium chloride, sodium bicarbonate pharmaceutical grades
  • Packaging materials for sachets (films, seals, printed substrates)

How many different PLENVU manufacturing sites are used across markets?

Answer: Not provided in the input.

What the manufacturing footprint typically shows

  • At least one bulk site and one finished-dose site per market authorization
  • Potential site substitutions over time due to GMP changes

What manufacturing/IP barriers affect alternative PLENVU supply or generic entry?

Answer: Not provided in the input.

What usually matters for colonoscopy-prep regimen competition

  • Formulation and method-of-use patent coverage (if applicable)
  • Regulatory comparability requirements for electrolyte composition and osmolality
  • GMP and packaging-line qualification for multi-sachet regimens

Key Takeaways

  • PLENVU supplier identification requires MAH and manufacturing-site data (from regulatory product listings) and release/distribution entities (from market authorizations and wholesale listings).
  • The prompt does not include the underlying MAH, authorization jurisdiction, label holder, or manufacturing-site records needed to produce a complete, accurate supplier roster.
  • A supplier map by company, function (bulk vs finished vs packaging vs release), and geography cannot be completed from the provided input.

FAQs

  1. Which company holds the EU/UK MA for PLENVU and who releases batches for the market?
  2. Are PLENVU manufacturing sites consistent across EU member states and the UK?
  3. Who makes the sachets and who performs final kit assembly for PLENVU regimens?
  4. If PLENVU is not FDA-approved, what regulatory listings govern supplier identification in the EU/UK?
  5. What documentation is used to trace PLENVU supply from bulk production to pharmacy dispensing?

References

(No sources were provided in the prompt.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.